BioArctic AB Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gunilla Christina Osswald
- Full Time Employees
- 131
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Warfvinges vag 35 Stockholm AB Sweden 112 51
- IPO Date
- Oct 12, 2017
- Website
- bioarctic.se
- Similar Companies
- Business
- BioArctic AB (publ) is a research-focused biopharmaceutical firm dedicated to the advancement of biological treatments for individuals afflicted with central nervous system disorders in Sweden and globally. The company's innovative pipeline emphasizes developing disease-modifying therapies for significant unmet medical needs in neurodegenerative conditions, notably Alzheimer's and Parkinson's disease. A cornerstone of its portfolio is Lecanemab (Leqembi®), a humanized monoclonal antibody designed to target and eliminate soluble amyloid-beta protofibrils, now approved for early Alzheimer's disease. This groundbreaking therapy was developed in collaboration with Eisai, who holds global development and commercialization responsibilities, with BioArctic retaining rights for co-commercialization within the Nordic region and receiving tiered royalties and milestone payments from global sales. Further advancing Alzheimer's research, a Lecanemab back-up program is currently in preclinical stages. In its pursuit of Parkinson's disease treatments, BioArctic initially developed ABBV-0805, a monoclonal antibody targeting alpha-synuclein aggregates. While AbbVie had partnered on this program and initiated Phase 1 trials, the collaboration was ultimately terminated in 2022, and BioArctic is now evaluating further development options for the asset. The company also had a program for spinal cord injuries, SC0806, involving a biodegradable device. However, clinical development for this candidate was terminated in 2019 following an interim analysis of Phase 1/2 data that indicated a lack of efficacy. BioArctic’s pipeline extends to other projects, including a PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program for Alzheimer's disease, featuring candidates BAN1503 and BrainTransporter-enabled BAN2803, which are partnered with Bristol Myers Squibb in a significant global licensing agreement. The firm additionally conducts research into novel antibodies for other neurodegenerative disorders such as ALS and enzyme deficiency diseases, alongside developing crucial imaging and biochemical biomarkers for Alzheimer's and Parkinson's. A key proprietary innovation is the BrainTransporter™ platform, a technology that significantly enhances the delivery of therapeutic antibodies and other biologics across the blood-brain barrier by leveraging the transferrin receptor, showing up to a 70-fold increase in brain penetration in preclinical models. This platform is central to several internal projects and has attracted new collaborations, including an option, collaboration, and license agreement with Novartis in August 2025 for an undisclosed neurodegeneration target, and a research evaluation agreement with Eisai in April 2024 for BAN2802. BioArctic is also exploring new technologies through an evaluation agreement with Beactica Therapeutics for its Eclipsor™ platform in CNS disorders. Established in 2000 and headquartered in Stockholm, Sweden, BioArctic AB (publ) continues its mission to address profound medical needs through scientific innovation. The company’s revenue model is largely driven by strategic partnerships, including upfront payments, milestone achievements, and royalties from global product sales.
Company News
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
BioArctic and Mesenkia enter oncology research collaboration
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
Bulletin from the Annual General Meeting in BioArctic AB (publ)
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
BioArctic Interim Report for the period January - March 2026
Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript
BioArctic Interim Report for the period October - December 2025
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Leqembi included in China's commercial insurance innovative drug list
New data on lecanemab to be presented at CTAD conference
Leqembi® approved for IV maintenance treatment in the United Kingdom
BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript
Interim Report for the period July - September 2025: BioArctic